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The progress in the isolation and characterization of tumor antigen (TA)-specific T
lymphocytes and in the genetic modification of immune cells allowed the clinical
development of adoptive cell therapy (ACT). Several clinical studies highlighted the
striking clinical activity of T cells engineered to express either Chimeric Antigen (CAR) or
T Cell (TCR) Receptors to target molecularly defined antigens expressed on tumor cells.
The breakthrough of immunotherapy is represented by the approval of CAR-T cells
specific for advanced or refractory CD19+ B cell malignancies by both the Food and Drug
Administration (FDA) and the European Medicinal Agency (EMA). Moreover, advances in
the manufacturing and gene editing of engineered immune cells contributed to the
selection of drug products with desired phenotype, refined specificity and decreased
toxicity. An important step toward the optimization of CAR-T cell therapy is the
development of “off-the shelf” T cell products that allow to reduce the complexity andorg January 2021 | Volume 11 | Article 5893811
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Frontiers in Immunology | www.frontiersin.the costs of the manufacturing and to render these drugs available for a broad number of
cancer patients. The Engineered Immune Cells in Cancer Immunotherapy (EICCI)
workshop hosted in Doha, Qatar, renowned experts, from both academia and industry,
to present and discuss the progress on both pre-clinical and clinical development of
genetically modified immune cells, including advances in the “off-the-shelf”manufacturing.
These experts have addressed also organizational needs and hurdles for the clinical grade
production and application of these biological drugs.Keywords: cancer, immunotherapy, CAR-T cells, TCR engineered lymphocytes, CAR-NK cells, monoclonal
antibody, clinical trial, off-the-shelf developmentINTRODUCTION
Cancer immunotherapy is aimed at a driving patient’s immune
system to attack tumor cells. The great advances achieved in this
field during the last two decades, lead to the emerging role of
immunotherapy as the “fifth pillar” of cancer treatment, together
with surgery, chemotherapy, radiotherapy and targeted therapy (1).
Adoptive cell therapy (ACT) with tumor antigen (TA)-specific
T lymphocytes has been clinically developed at an unparalleled
pace (2–4). In particular, the approach of the genetic engineering
of T or NK cells to target and destroy cancer cells, revealed as
powerful and, in some cases, unprecedented in term of clinicalVirus; ACT, Adoptive Cell Therapy;
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org 2success for the treatment of patients with aggressive malignancies,
refractory to other therapeutic interventions (5–7).
T cells engineered with chimeric antigen receptors (CARs), that
combine the antigen binding region of antibodies and T cell
signaling domains responsible for activation (8), represented the
breakthrough of cell-based immunotherapy (1, 2, 3). Different
CARs have been engineered to target a variety of antigens
expressed by either hematologic or solid tumors, that are listed
by Sadelain and colleagues (9). The initial clinical application of
CAR-T cells was quite disappointing in terms of patients’
responses, due to the inefficient expansion and persistence of
CAR-T cells in vivo (10–12). Additional modifications of the
structure of CARs, by including co-stimulatory domains allowed
the achievement of clinical benefit through the treatment of
patients with B cell malignancies overexpressing CD19 (13–18).
Strikingly response rates in the range of 57%–82%, with complete
response rate of 52-60%, were detected upon the infusion of
CD19-CAR-T cells in patients with B cell malignancies
refractory to prior treatments (7, 8, 9). These results led to the
accelerated approval by both FDA and EMA of two drug products:
1. tisagenlecleucel/Kymriah for the treatment of children and
young adult with acute lymphoblastic leukemia (ALL) (13, 14,
19–21), and for the treatment of adults with relapsed/refractory
Diffuse Large B cell lymphoma (DLBCL) (22).
Axicabtagene Ciloleucel/Yescarta for the Treatment of Adult
Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
(NHL), including Table 1 (14, 16, 18).
More recently, a third product, brexucabtagene autolucel
(Tecartus) has been approved for the treatment of relapsed or
refractory mantle cell lymphoma. This approval was granted based
on the results of the ZUMA-2 (NCT02601313) clinical trial, showing
87% of ORR, with a complete remission (CR) rate of 62% (23).
CAR-T cells represent promising therapeutic options also for
solid tumors, although they are still under clinical development and
do not yet have proven their clinical efficacy (Table 1) (24). The
principal limitations for their clinical activity are: i. paucity of tumor
specific antigens and ii. the low efficiency of T cells in penetrating
the tumor microenvironment and homing to the tumor site, and iii.
their limited functional activity within the tumor (24).
In addition, efforts are ongoing at different leading groups to
develop allogeneic CAR-T cell therapies, in order to simplify the
manufacturing process, to reduce the costs and rendering these
drugs available to larger cohorts of patients (Table 1).January 2021 | Volume 11 | Article 589381
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approach of engineering T lymphocytes with TA-specific T Cell
Receptor (TCR) for the treatment of solid tumors and multiple
myeloma, including patients with advanced metastatic
malignancies (Table 2) (2, 4, 25–31). This methodology has
been applied for the generation of high avidity tumor-specific T
cells. The choice of the targeted antigens is critical for the efficacy
of this type of therapy and to prevent off-target reactivity (32,
33). The targeting of overexpressed antigens and neo-antigens,
that are not shared with non-embryonic normal tissues, can lead
to the cell-mediated killing of tumor cells without severe
toxicities due to the targeting of normal tissue(s) (27–29, 34, 35).Frontiers in Immunology | www.frontiersin.org 3Gene editing through the targeted knock out of genes or the
insertion of suicide genes represents an innovative strategy that has
been applied to tumor-specific engineered immune cells with the
aims of either increasing their specificity and in vivo persistence or
decreasing the induction of possible toxicities or allogeneic rejection,
respectively (36–39). The application of this technique allowed also
to generate universal/”off-the-shelf” CAR-T cells using the
peripheral blood of healthy volunteers as source of immune cells
(40–47). This strategy is currently under clinical development with
few clinical trials ongoing in EU and USA (42, 44, 48).
All the topics mentioned above have been addressed in a
comprehensive manner in the context of the first internationalTABLE 1 | Summary of principal clinical studies of CAR-T/NK cells.
Trial
registration N.
Sponsor Country Agent/ cell source and type Indication Note
NCT03601442 Novartis Pharmaceuticals US LV CAR-T (CTL019) B-ALL/B cell lymphomas Available in the
market
(Kymriah)
NCT02348216 Kite Pharma US RV CAR-T (KTE-C19, Axi-cel) B-ALL/DLBCL Available in the
market
(Yescarta)
NCT02601313 Kite Pharma US 2nd generation -Autologous anti-CD19
CAR-T cell
Mantle Cell Lymphoma Available in the
market
(Tecartus)
NCT01044069 Kite Pharma US 2nd generation -Autologous anti-CD19
CAR-T cell
CLL, Phase 1/2
NCT01593696 NCI US 2nd generation -autologous anti-CD19
CAR-T cell
NHL, ALL, CLL Phase 1/2
NCT00586391 Baylor College of Medicine,
Texas Children’s Hospital
US 2nd generation -Autologous anti-CD19
CAR-T cell
Non-Hodgkin’s lymphoma, ALL, CLL Phase 1/2
NCT00924326 NCI US Anti-(CD19)-CAR PBL Primary Mediastinal B-cell Lymphoma,
Diffuse Large B-cell Lymphoma, mantle
cell
Phase 1/2
NCT01626495 Children’s Hospital of
Philadelphia, University of
Pennsylvania
US 2nd generation -Autologous anti-CD19
CAR-T cell
B-ALL, CD19+ Leukemia and Lymphoma Phase1/2
NCT03056339 M.D. Anderson Cancer Center US Allogeneic CD19-CD28-zeta-2A-
iCasp9-IL15-transduced cord blood-
NK cells
Refractory B cell Malignancies Phase 1





Allogeneic UCAR19 Pediatric patients with relapsed or
refractory CD19+ B-ALL
Phase 1
NCT02208362 City of Hope Medical Center US Autologous anti-IL13Ra2 CAR-T cell Glioblastoma Phase 1
NCT00902044 Baylor College of Medicine US Autologous HER2-CAR-T cells Sarcoma Phase 1





NCT04097301 MolMed Italy Autologous CD44v6 CAR T-cells-
HSV-TK Mut2 gene
Multiple Myeloma Phase 1/2
– National Cancer Institute US (EGFRv)III Chimeric antigen receptor
(CAR) transduced PBL




– Glycostem Therapeutics Allogeneic cord blood-derived CD19-
NK cells (oNKord®)
Elderly AML Phase 1
NCT03294954 Baylor College of Medicine US 2nd generation -anti-GD2-IL15+CAR-
NKT cells
Neuroblastoma Phase 1January 2021 | Volume 11AML, Acute Myeloid Leukemia; BCMA, B-Cell Maturation Antigen; CD44v6, CD44 Variant 6; GD2, Disialoganglioside; HSV-TK Mut2, Mutated Herpes Simplex Virus Thymidine Kinase;
IL13Ra2, Interleukin 13 Receptor Subunit Alpha 2; LV, Lentiviral Vectors; NCI, National Cancer Institute; NKG2D, C-Type Lectin-Like Receptor RV, Retroviral Vectors; UK, United Kingdom;
US, United States; ALL, Acute lymphoblastic leukemia; CLL, Chronic Lymphoblastic Leukemia.| Article 589381
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immunotherapy: from discovery to off-the-shelf development”
(15th–16th February 2019, Doha, Qatar). Renowned speakers
from both academia and industry who pioneered the field
gathered in Doha bringing high level discussions on scientific
and clinical advances and bringing the participants at the
forefront of this rapidly evolving topic. A satellite mini-Frontiers in Immunology | www.frontiersin.org 4symposium at the initial opening of the workshop, through its
educational contents, has provided basic knowledge of cancer
immunology, immunotherapy and cell-based therapies to health
care practitioners, researchers and students. Poster sessions
have also offered the opportunity for active involvement of
young researchers and under-graduate students. This report
summarizes key data and highlights from each session.TABLE 2 | Summary of principal clinical studies of TCR-engineered T cells.
Trial
registration
Sponsor Country Agent/ cell source and type Indication Note
NCT01967823 NCI US Anti-NY-ESO-1 mTCR NY-ESO-1 Expressing Cancers Phase 2
NCT02111850 NCI US Anti-MAGE-A3-DP4 TCR Various solid metastatic tumors (Targeting MAGE-
A3) in HLA-DP04 positive patients
Phase 1/2
NCT02408016 Fred Hutchinson Cancer
Research Center/NCI
US WT1-TCRc4 Tcm/Tn Lymphocytes Non-small Cell Lung Cancer, Mesothelioma Phase 1/2
NCT01621724 Cell Medica Ltd/University
College, London/Cell
Therapy Catapult





US NY-ESO-1 TCR Synovial Sarcoma Phase 1/2
– GlaxoSmithKline/
Adaptimmune
US NY-ESO-1 TCR Non-small Cell Lung Cancer Phase 1/2
– GlaxoSmithKline/
Adaptimmune
US NY-ESO-1 Ovarian cancer Phase 1/2
NCT03139370 Kite Pharma US KITE-718 (MAGE-A3/A6) TCR MAGE-A3/A6-positive solid tumors Phase 1/2




US NY-ESO-1 TCR Multiple myeloma, Sarcoma, Melanoma Phase 1/2
NCT02840110 Unum Therapeutics Inc. US ACTR TCR Multiple Myeloma Phase 1/2





US IMA-201 Various solid tumors (Head and Neck Squamous
Cell Carcinoma,
Non-small Cell Lung Cancer)
Phase 1
NCT03912831 NCI/Kite Pharma US KITE-439 HPV16+ Tumors (relapsed or refractory) Phase 1
– Fred Hutchinson/Juno US Anti-mesothelin TCR Pancreatic cancer
NCT01567891 Adaptimmune US Enhanced TCRs Specific for NY-ESO-1 Refractory Ovarian Cancer Phase 1/2
NCT03412877 NCI US Autologous T-Cells Genetically Engineered to
Express T-Cell Receptors Reactive Against
Mutated Neoantigens in People With Metastatic
Cancer
Glioblastoma





NCT03907852 TCR2 Therapeutics US Autologous genetically engineered T cells







Non Small Cell Lung Cancer
Non Small Cell Lung Cancer Metastatic
Phase 1/2
NCT04323657 TCR2 Therapeutics US Autologous genetically engineered T cells






Primary Mediastinal Large B Cell Lymphoma
CML
FL
Phase 1/2January 2021 | Volume 11 | ArtiHPV, Human Papilloma Virus; EGFRVIII, Epidermal Growth Factor Receptor Variant III; NY-ESO-1, New York Esophageal Squamous Cell Carcinoma 1; PRAME, Melanoma Antigen
Preferentially Expressed in Tumors; MAGE, Melanoma Antigen; WT1, Wilms Tumor 1; NCI, National Cancer Institute; US, United States; AML, Acute Myeloid Leukemia; CML, Chronic
Myelogenous Leukemia; DLBCL, Diffuse Large B Cell Lymphoma; FL, Follicular Lymphoma.cle 589381
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During the past few years, CAR-T cells, either CD28/CD3z (4, 5)
or 4-1BB/CD3z CARs (6), targeting CD19+ B cell malignancies
have demonstrated safety and clinical activity in the context of
multiple Phase I/II clinical trials (68). These products have been
used for the treatment of either pediatric and adult patients with
relapsed or refractory ALL, showing high CR rate (49–54).
Similarly, CD19-CAR-T cells showed impressive clinical
activity in relapsed/refractory pediatric-adolescent or adult
Non-Hodgkin Lymphoma (NHL) with 40-63% of CR (58, 60,
68–70). These unprecedented results lead to the rapid approval
by both FDA and EMA and the commercialization of these
Advanced Therapeutic Medicinal Products (ATMPs) (61, 62).
Associate Prof. Cameron Turtle (Fred Hutchinson Cancer
Research Center, USA) kicked off the first session of the workshop
with a keynote lecture summarizing the aforementioned results
and focusing on the factors impacting the response to CD19
targeting CAR-T cell immunotherapy in adults with ALL and
NHL in a clinical trial at Fred Hutchinson Cancer Research
Center, Seattle, WA. Different factors were found to affect the
patients’ clinical responses, including the dose of infusion of CAR–
T cells, their cellular expansion and persistence in vivo, the tumor
burden, and the conditioning regimen used for lymphodepletion
(49, 61). Low levels of circulating CAR-T cells were identified as one
of the mechanisms of resistance to CAR-T cell therapies. In some
ALL patients, antigen loss was observed in tumor cells following
the treatment with CD19-CAR-T cells, as a consequence of
either missense mutations or alternative splicing of the CD19
encoding gene (63–65). In ALL patients low levels of lactate
dehydrogenase (LDH) and normal platelet counts in the blood
prior to lymphodepletion followed by the treatment with
cyclophosphamide/fludarabine (Cy/Flu) compared to Cy regimen
alone were identified as factors associated with better disease-free
survival (DFS) (61). Furthermore, DFS was improved in ALL
patients who achieved minimal residual disease (MRD)-negative
CR after CAR-T cell therapy and underwent allogeneic
hematopoietic stem cell transplantation compared to those who
did not undergo transplantation. In NHL patients, high levels of
serum LDH before lymphodepletion, and low MCP-1 and IL-7
before or shortly after CAR-T cell infusion were associated
with shorter progression-free survival after treatment with CD19-
CAR-T cells (66).
CD19-CAR-T cells represented salvage therapy also for
patients diagnosed with NHL, including advanced DLBCL,
primary mediastinal B-cell lymphoma (PMBCL) and follicular
lymphoma (FL). Complete responses (CR), 49%–71%, have been
observed in these patients, with a median (overall survival) OS
greater than 2 years (16, 18, 22, 59, 67). FDA and EMA approval
for axicabtagene ciloleucel in relapsed and refractory DLBCL was
granted based on results of the multi-center Phase 2 ZUMA-1
trial, presented in a keynote session by Dr. Frederick L. Locke
(Moffitt Cancer Center). Lisocabtagene maraleucel (Liso-cel;
JCAR017) represents another CAR-T-cell-based therapy for
aggressive NHL patients that is composed by 1:1 ratio of bothFrontiers in Immunology | www.frontiersin.org 5CD4+ and CD8+ T cells. In the context of the multicenter
TRANSCEND-NHL-001 trial, an overall response rate (ORR)
of 73% [95% CI, (67–78)] was observed. The CR rate was 53%
[95% CI, (47–59)] with a median follow-up of 12 months (67). It
appears lower frequencies of toxicities may have occurred in the
TRANSCEND trial, as well as the JULIET trial that tested
tisagenlecleucel in DLBCL; both of these therapeutic products
contain the 4-1BBz costimulatory molecule, in contrast to axi-cel
which contains a CD28z costimulatory molecule (58, 67–69). It
should be noted that these trials used different toxicity grading
systems, so comparisons should be interpreted with caution.
The usage of mathematical and statistical modeling to
evaluate the efficacy of CD19-CAR-T cell-based clinical trials,
revealed that multiple factors, including the frequency of
memory T cells in the circulation, the tumor burden and the
inflammatory cytokine profile, can affect the extent and duration
of patients’ clinical responses (70). The most frequent toxicities
attributed to CAR-T cells are the cytokine release syndrome
(CRS) and neurologic events. In the majority of cases they are
reversible. CRS can usually be controlled by the administration of
tocilizumab (anti-IL-6 mAb) with or without corticosteroids
(69–71). Therapies for neurotoxicity are less well-defined, but
usually involve anti-seizure prophylaxis and corticosteroids,
with addition of tocilizumab (anti-IL-6 mAb) only if there
is concurrent CRS. Patients presenting with severe pro-
inflammatory conditions, quantified by serological increase
in C-reactive protein and ferritin, before the injection of CAR-
T cells appear to be at higher risk for toxicities and might
benefit from treatment with immunomodulatory agents
before the toxicities become severe (18, 66, 71–73). Safety
cohorts of ZUMA-1 tested at early stage and the prophylactic
administration of tocilizumab, showed reduced frequency
of severe CRS but not neurotoxicity. In this study, the
development of neurological toxicity was associated with
higher level of CD14+ myeloid cells and CD4+ CAR-T cells in
the cerebrospinal fluid (CSF), again implicating a pro-myeloid
inflammatory state associated with CAR T toxicity (66, 71–74).
These observations highlight that multiple factors could affect
patients’ outcome and the development of toxicities; further
studies are required to confirm the role of the association of
these parameters as biomarkers predicting the risk to develop
toxicities upon CAR-T cell treatment.THE HEMATOLOGY/ONCOLOGY
LANDSCAPE IN QATAR
According to registry data from 2015, leukemia represents the 5th
most common malignancy in Qatar across genders and
nationalities. NHL, including DLBCL, is the 4th most common
cancer among males and represents the most frequent lymphoid
malignancy in Qatar with about 46% of all lymphoid
malignancies. The average OS of DLBCL patients has been
reported as 64% between 2013 and 2017. However, 30% to
40% of patients has a high risk of relapse from the first line of
chemotherapy treatment, and 10% to develop refractory disease,January 2021 | Volume 11 | Article 589381
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(75). Dr. Ruba Y. Taha (NCCCR-HMC, Qatar) summarized the
available therapeutic options for these patients, including the
treatment with platinum- and cytarabine-based regimens alone
or prior to autologous HSCT (PARMA prospective multicenter
study) (76). Patients enrolled in this study with early relapses
showed similar clinical outcome as incomplete responders (77).
However, these patients have superior clinical benefit from the
usage of monoclonal antibodies targeting antigens expressed by
blasts (CD19, CD20, CD22, and CD52) as compared to
chemotherapy or targeted therapy (53). Therefore, the availability
in Qatar of CAR-T cell therapy targeting the aforementioned
antigens will provide further options to improve the OS of
patients with relapsed/refractory DLBCL. A limited number of
patients can benefit from this type of therapy only upon
admittance to international clinical centers.
Qatar Cancer Society (QCS) is a charity that was founded in
1997 dedicated to implement the research in this field and
orchestrate a community partnership platform to make Qatar
among the leading countries in cancer prevention and burden
control (Dr. Hadi Mohamad Abu Rasheed, QCS, Qatar). In this
context, QCS is facilitating the access of Qatari patients to
innovative therapies such as CAR-T cells. A testimonial of a
patient with a diagnosis of NHL who underwent a successful
CD19-CAR-T cell treatment in US, was presented during the
conference, corroborating the need of implementing local efforts
and research in this field.
The pediatric cancer genome project showed the differential
make-up of driver mutations and related aberrant molecular
pathways in these patients as compared to adult cancer patients’
profile (78). These evidences indicate the need to deeply
understand the disease’s mechanisms of children with cancer
in an attempt to allow early detection and intervention. The
comprehensive biological characterization of pediatric leukemia
ongoing at Sidra Medicine (Dr. Chiara Cugno, Sidra Medicine,
Qatar) is aimed at identifying dysregulated signaling pathways to
contribute to the development of precision medicine treatments.
These investigations might also lead to identifying novel target
molecules for CAR-T cells or the optimization of targeting
multiple antigens in relationship with the evolution of the
disease and possible development of resistance to this therapy
(79, 80).TARGETING TUMORS WITH TCR
ENGINEERED T LYMPHOCYTES
ACT studies with T cells engineered with TA-specific TCR,
provided evidences of their clinical success (Table 2) (2, 28–31,
34, 81, 82). Nevertheless, the improvement of the efficacy, the
tumor specificity and strategies to overcome the competition in
the synthesis of TCR between exogenous and endogenous alpha
and beta chains are subjects of multiple novel investigations. In
addition, the usage in most of the cases of epithelial-derived
TAAs, that are shared with normal tissues can induce “off-target”
toxic effects. The accurate choice of TAAs selectively expressedFrontiers in Immunology | www.frontiersin.org 6by tumor cells and/or by the associated blood vessels and
microenvironment can overcome the unwanted unspecific
targeting and the related toxicities.
These topics were addressed by the presentations, that are
summarized in paragraphs 4 and 5, discussing advanced tools to
implement the engineering of T and NKT lymphocytes and refining
the selection of TAs to redirect the cell-mediated responses.
Prof. Chiara Bonini, (San Raffaele Scientific Institute, Milan,
Italy) presented the application of genetic knock-out (KO) and
gene substitution approach to introduce TA-specific TCRs in T
lymphocytes. This aim was achieved through the transient
exposure of T cells to alpha and beta chain specific Zinc Finger
Nucleases (ZFNs), followed by the introduction of lentiviral
vectors (LV) encoding for a “novel” TCR (83). This study was
focused on targeting the leukemia-associated TAWilms’ tumor 1
(WT1), that is a zinc finger DNA-binding protein acting as
transcription factor and playing an important role in cell growth
and differentiation of cells (84). The enrichment of T cell
memory stem (TSCM) (85, 86) cells that are “younger” cells
with persistence and survival properties and delayed ageing and
exhaustion (87) occurred for TA-specific T cells. This population
of T cells was found to be enriched in the circulation of patients
following HSCT and the infusion with T lymphocytes genetically
modified to express the thymidine kinase (TK) suicide gene (88,
89). This phenomenon was observed also following long term
treatment with engineered T cells (87), indicating that both
antigen exposure and the phenotype of the infused cells can
affect their in vivo survival and the diversification of their
immunological memory (89). ACT can benefit from HSCT
platforms followed by the infusion of TCR engineered with
gene editing technology in inducing the Graft-versus-tumor
(GvT) effect in hematological malignancies (90).
The transfer of lipid specific TCRs into T cells represents
another innovative approach for the ACT of leukemia. T cells
can recognize lipid antigens presented by MHC class I-related
CD1 molecules (CD1a, b, c, d). These T cells are involved
in antimicrobial immunity and, in case of reactivity against
CD1-presented self-lipids, in autoimmunity and cancer
immunosurveillance (91). Dr. Giulia Casorati (San Raffaele
Scientific Institute, Milan, Italy) demonstrated that primary
acute myelocytic leukemia (AML) leukemia and B-ALL blasts
express CD1c and are recognized by a group of CD1c self-
reactive T cells specific for methyl-lysophosphatidic acids
(mLPAs). mLPAs is a self-lipid antigen highly enriched in
malignant cells that might play a role in leukemia growth.
Lipid antigens are also less susceptible to mutation and
immune mediated selection (92, 93). The anti-tumor activity in
vitro and the control of the progression in vivo of leukemia cells
by T cells engineered with mLPA-specific TCRs has been
assessed, showing that these T cells could represent novel and
efficient tools for ACT for leukemia patients either in the
prophylactic setting at the time of HSCT or at post-transplant
relapse of the disease (93).
A novel high-throughput technology, XPRESIDENT®, has
been applied to identify and qualify peptides derived from TAAs
(Dr. Ali Mohamed, Immatics, Tubingen, Germany and Houston,January 2021 | Volume 11 | Article 589381
Guerrouahen et al. Proceeding From the First EICCI Workshop in DohaTX, USA). This platform, through the combination of ultra-
sensitive mass spectrometry (LC-MS/MS) with quantitative
transcriptomics, was able to identify the differential expression
of HLA-bound peptides in tumor vs. normal tissues. Taking
advantage of this platform, several T cell-based therapy
programs have entered clinical development. These include the
targeting of multiple TAAs with T cells expressing either native
or exogeneous TCR. A robust clinical grade manufacturing
process has been developed for autologous TCR transduced T
cells that implied 7–10 days of manufacturing, (IMA201 and
IMA202) or 5–6 days (IMA203), shortening the timeline
required for the production in autologous setting. An
interesting strategy was based on the engineering of allogeneic
gd T cells, that display inherent anti-tumor activity, the ability to
infiltrate tumor tissues and MHC-independent reactivity, with
exogenous TA-specific ab TCR (ACTallo® IMA301). Therefore,
these cells acquire abT cell features in the absence of the risk to
develop allogeneic reactions or GvHD due to HLA mismatching
(94, 95). Additionally, the development pipeline includes T-cell
Engaging Receptors (TCER®s). These bispecific TCR molecules
are soluble fusion proteins with two binding domains: (i) a TCR
domain that recognizes a tumor-specific peptide presented by
HLA class I, and (ii) a T-cell recruiting antibody domain, which
allows the recruitment and activation of T cells to attack
the tumor.OPTIMIZING THE DELIVERY IN VIVO OF
CAR-T CELLS AND THEIR REDIRECTION
TO TUMORS
The gene transfer platforms for therapeutic application can occur
either by isolating ex vivo the cells for modification and the
subsequent re-infusion in the patients or in vivo through viral
vectors (LV or adenovirus, AAV). The vector delivery can be
controlled via particle-receptor interactions. The engineering
process for specific targeting involves the mutation of the
receptor binding sites and adding the desired target domains
in these regions (96). Designed ankyrin repeat proteins
(DARPins) can recognize target receptors with high
specificities and affinities and when ligated into vectors
mediate cellular binding (97). Prof. Christian Buchholz (Paul-
Ehrlich-Institut, Federal Institute for Vaccines and
Biomedicines, Langen, Germany) discussed the selective
delivery of CARs into CD8+ T lymphocytes for the in vivo
generation of CAR-T cells. LVs that can specifically transduce
human CD8+ cells have been used to deliver the CD19-CAR in
vivo into immunodeficient mice transplanted with human
peripheral blood mononuclear cells (PBMCs). The vector
administration in fully humanized mice transplanted with
human CD34+ cells induced TA-specific CAR-T cells depleting
the CD19+ B lymphocytes. Signs of CRS, the presence of tissue‐
invading CAR-T cells and the complete elimination of the B‐
lymphocyte‐rich zones in spleens were detected (98). More
recently, efficient eradication of tumors in transplanted miceFrontiers in Immunology | www.frontiersin.org 7was demonstrated upon a single vector injection (99). Although
further investigations are desirable, these promising results have
demonstrated that the in vivo engineering of human CD8+ CAR-
T cells could substantially simplify their manufacturing and the
development of future cell-based immunotherapies.
Prof. Soldano Ferrone (Massachusetts General Hospital,
Harvard Medical School, Boston MA, USA) has dedicated
many efforts to elucidate the immunogenic properties of
human chondroitin sulfate proteoglycan (CSPG)-4 and its
expression on the membrane of different types of cancer cells,
including cancer initiating cells (100–104). This molecule is
also known as high molecular weight-melanoma associated
antigen (HMW-MAA), or neuron-glial antigen 2 (NG2).
CSPGs are key bioactive molecules which play a role in
cancer cell growth, migration and neo-angiogenesis (105).
This antigen can be upregulated on cancer cells incubated
under hypoxic conditions and is not or poorly expressed on
normal cells with the exception of pericytes in the TME. Prof.
Ferrone’s team has previously isolated the mAb scFv-Fc C21
specifically reacting with CSPG4 (100, 101) and he pointed out
that some of the commercially available antibodies, including
those used to generate the information about CSPG4 presented
in the Atlas of Proteins, have the wrong specificity. This has
generated some of the misleading information presented in the
Atlas of Proteins. CSPG4 represents a target TA for T cell-
mediated responses (101, 105–107). In addition, the availability
of specific mAbs for this antigen has allowed the generation of
CAR-T cells targeting either epithelial cancers, such as triple
negative breast cancer, squamous cell carcinoma of head and
neck and glioblastoma (106, 108–110). Interestingly, cancer
initiating cells isolated from these types of cancers could be
efficiently recognized and killed in vitro by CSPG4-CAR-T cells
(108, 110). The anti-tumor activity of CAR-T cells targeting
CSPG4 was potentiated through the intratumoral injection of
effector cells. These pieces of evidence suggest the relevance of
CSPG4 as target TA of CAR-T cells.
The development of novel scFvs, through the generation and
screening of monoclonal antibodies targeting TAAs, can be
applied to redirect engineered T cells for the targeting of
colorectal cancer stem-like cells (CRC-SC; Dr. Eleonora
Ponterio, Catholic University and Fondazione Policlinico
Universitario “A. Gemelli”-I.R.C.C.S. Rome, Italy; Oral poster
presentation). This approach represents a novel framework to
implement the efficacy of CAR-T cells for solid tumors. Through
the injection into mice of primary CRC-SC, antibody-mediated
immune responses selectively binding to CRC tissues and not to
normal mucosa have been generated. Upon sequencing of the
variable chains of these mAbs, the scFv was tagged with a constant
fragment (Fc) and used to isolate, through immunoprecipitation,
the recognized TAs. The scFvs have been then shuttled into LVs
encoding for either 2nd or 3rd generation CARs and used to
transduce the immortalized T cell line Jurkat. These cells, upon
the activation of the CAR through the co-culture with CRC-SC,
secreted IL-2. The isolated mAbs could represent a powerful new
tool to direct T cells against CRC [unpublished data and
see (111)].January 2021 | Volume 11 | Article 589381
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cancer phenotypes could contribute to understand patient’s
clinical outcome and the responsiveness to immunotherapy. A
pan-cancer analysis of the TCGA dataset has revealed that a pre-
existing intratumoral T helper (Th-1) immune response can affect
the OS of cancer patients with variable outcome depending on the
histological origin of tumor. This indicates that cancer-specific
pathways modulate the prognostic power of anti-tumor immune
response and shape the TME and the type of immune infiltrating
cells (Jessica Roelands, PhD Student, Sidra 805 Medicine, Qatar;
Oral poster presentation) (112–115). These observations can play
a role in the stratification of cancer patients. The clinical relevance
of these findings was demonstrated using a dataset of melanoma
patients treated with checkpoint inhibitors. A high expression of
genes reflecting Th-1 anti-tumor responses in pretreatment
samples was associated with improved survival only for samples
with high proliferation scores, or with low TGF-b expression
(115). The investigation of these parameters in tissues form large
cohorts (N=366) of CRC patients represents a valuable tool to
either predict the responsiveness of patients to immunotherapy or
to identify novel target molecules for immune-based therapies.MANUFACTURING IMPLEMENTATION OF
ENGINEERED T CELLS AND PHARMA/
BIOTECH PERSPECTIVES
The manufacturing of CAR-T cells over the time underwent a
rapid evolution, from the 1st until the 3rd generation of CAR-T
cells, depending on the structure and number of co-stimulatory
molecules included in the signaling portion of the receptor. The
choice of 2nd generation CAR-T cell for therapeutic application
resulted from the practical need to offset toxicity rather than to
achieve greater anti-tumor efficacy. Further advances are the
“armored” CAR-T cells. These represent genetically modified
T cells bearing CARs that comprise in their structures
immunomodulating agents such as: i. proinflammatory
cytokines; ii. secreted antibodies or their part bearing antigen
specificity; iii. costimulatory ligands (Dr. Renier Brentjens,
Memorial Sloan Kettering Cancer Center, USA). Armored
CD19-CAR-T cells bearing the murine IL-18 (mIL-18 CAR-
T) showed in in vivo models enhanced expansion and
persistence, anti-tumor activity and prolonged B cell aplasia
(up to 150 days after treatment), dependent on autocrine IL-
18R signaling (116), even without prior chemotherapy
conditioning. Whereas, without preconditioning of mice,
the anti-CD19 CAR-T cells failed to prolong the survival of
animals in a syngeneic tumor model (117). Through targeted
delivery of IL-18 to the tumor, mIL-18 CAR-T cells can
modulate the tumor microenvironment, recruit, and activate
endogenous anti-tumor immune effector cells, which in turn
orchestrate an effective anti-tumor response beyond the CAR-
specific targets (116). Programmed cell death-1 (PD-1)/ligand
(PD-L1) signaling represents one of the immune checkpoints
that can modulate CAR-T cell-mediated responses when they
encounter either tumor cells or TME. Armored CAR-T cellsFrontiers in Immunology | www.frontiersin.org 8endowed with the capacity to secrete anti-PD-L1 scFv showed
enhanced in vivo anti-tumor activity, persistence and survival
in a PD-L1+ tumor model. PD-1-blocking Ab produced by
CAR-T cells can also enhance the activity of tumor-specific
“bystander” T cells present in TME. Unlike the usage of
systemic checkpoint blockade therapy with monoclonal
antibodies, the scFv secreted by CAR-T cells penetrate
and remain in the TME improving their anti-tumor activity
(118). Moreover, the safety of these armored CAR-T cells is
superior than checkpoint blockade systemic therapy (118). The
third example of armored CAR-T cells comprise the
immunostimulatory CD40 ligand (CD40L), that is a type
II transmembrane protein belonging to the TNF receptor
family. CD40L expressing CAR-T cells displayed enhanced
proliferation and secretion of proinflammatory cytokines, e.g.,
IFN-g and GM-CSF (119). These armored effector T cells
demonstrated enhanced cytotoxic activity both in vitro and in
vivo for both CLL and NHL models (119, 120). All together,
these evidences, indicate the promising clinical efficacy of next
generation armored CAR-T cells.
The clinical grade manufacturing of CAR-T cells can be
challenging due to the complexity of the process. The
collaboration between biotech and researchers in academia can
result in the development of novel technological platforms to
support researchers and physicians from discovery to the clinical
development of cell therapy (64, 121). One example is represented
by the automated closed system production of engineered T cells
that can perform all phases of CAR-T cell generation, from
magnetic T-cell enrichment, activation, viral transduction and
expansion to downstream harvest for cryopreservation/infusion
(CliniMACS Prodigy system). The progress in the generation of
this type of system allow standardization of processes facilitating
transfer between different manufacturing facilities while the
flexibility of the manufacturing platform supports the rapid
transfer of innovative cell therapies to the clinic (Dr. Ian
Johnston, Miltenyi Biotec B.V. & Co. KG, Germany).GENETIC ENGINEERING OF CELLS AND
GENE EDITING
Genetic engineering can act on the core functioning of cells,
including reprogramming, differentiation, migration, fitness, and
proliferation. In addition, gene therapy is aimed at correcting
genetic and degenerative diseases. Novel tools have been
developed for the precise engineering of immune cells.
Retroviral vectors (RVs), one of the most effective approaches
to the modification of genes, display the ability to integrate at
various positions in the genome. This implies the risk of
mutagenesis in the course of the integration of vectors into the
genome. Studies on animal models have revealed evidence of
leukemia induction in a process of insertional mutagenesis
mediated by retroviral vector (122). The utilization of constructs
with improved safety, such as the low-risk recombinant
alpharetroviral SIN vectors (aRV) can prevent the genotoxicity
caused by insertional mutagenesis (Prof. Axel Schambach,January 2021 | Volume 11 | Article 589381
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neutral integration pattern, lowering the risk of insertional
mutagenesis as compared to gammaretroviral and LV (123,
124). Given that aRV vectors do not have the tendency to
integrate their cargo into promoter/enhancer regions as well as
gene bodies, insertional damages arising from the integration of
aRV are lower as compared with other RVs. LVs are considered
relatively safe due to their tendency to insert into genes instead to
the transcriptional sites that may lead to insertional mutagenesis.
The usage of transient retroviral platform, such as the retroviral
episome transfer (RET), allows a controllable transgene
expression, low or absence of cytotoxicity and the option for cell
targeting (123, 124).
Genome editing tools like CRISPR/Cas9, transcription
activator-like effector nuclease (TALENs), zinc fingers nuclease
(ZFNs), Mega-tal and HEs provide a precise method for the
genetic engineering of cells. These platforms introduce double
strand breaks (DSBs) in the genome that can be repaired either
by non-homologous end-joining (NHEJ) causing disruption of
the genes or by homologous recombination which happens at
lower rates allowing nucleotide modification of the genome.
CRISPR/CAS9 platform requires the co-delivery of a single
guide RNA (sgRNA), representing the bottleneck of this
strategy. The MS2 bacteriophage RNA packaging mechanism
has been applied to the production of non-integrating RVs,
GV.MS2-CRISPR/Cas9 all-in-one particles, for efficient gene
editing (125, 126). This strategy led to efficient KO of target
genes, such as TP53 in human fibroblasts or CXCR4 or CCR7 in
Jurkat or T cells, respectively (125–127). These platforms are
applicable to the generation of allogeneic CAR-T cells to prevent
GvHD and/or to engineer their immune functions.
The usage of ribonucleoproteins (RNPs) as the primary mode
of gene editing variants of high-fidelity Cas9 (IDT HiFi SpCas9)
enabled better gene-editing by reducing levels off-target INDELs
as identified by bioinformatics tools (e.g., COSMID, guide-seq
genome-wide profiling of target cells or circle-seq in vitro screen
for genome-wide CRISPR/Cas9 nuclease off target) (Prof.
Matthew Porteus, Stanford University, San Francisco, CA,
USA) (128). This represents an efficient tool for CD19-CAR-T
cell to lower the associated toxicities and implement the anti-
tumor activity. CD19-CAR-T cells employed with the KO of
TCRab to avoid GvHD were assessed in the context of infusions
before and following TCRab-depleted haploidentical-HSCT
(129). This was achieved through the targeting of the locus of
TCR (TRAC) with CRISPR/CAS9 non-integrating AAV6
encoding forCD19-CARs. The engineered T cells showed
active anti-tumor activity against CD19+ leukemia xenografts
(Nalm6 cells in NSG mice). No off-targets indels was detected in
these CAR-T cells through the usage of HiFi Cas9 (129). In order
to improve further CAR-T cell efficacy and safety, in 2017, Dr
Eyquem et al. (130) used complex genome editing tool to
demonstrate that TCR-like expression of the CAR improve
CAR-T therapeutic activity. However, genome editing tool to
demonstrate that TCR-like expression of the CAR improves
CAR-T therapeutic activity. In this direction, Prof. Francisco
Martin (Pfizer-University of Granada-Junta de Andalucıá CentreFrontiers in Immunology | www.frontiersin.org 9for Genomics and Oncological Research, GENYO, Spain)
presented an interesting approach to facilitate clinic translation
of TCR-like CAR-T cells. Dr. Martin´s team constructed LVs
that closely followed the expression profile of the TCR upon CD3
stimulation and generated CAR-T cells using the LVs (Patent
PCT/EP2019/081346, “Polynucleotide for safer and more effective
immunotherapy” and unpublished data). These physiological
CAR-T cells showed strong resistance to exhaustion upon
repeated stimulation and showed potent in vivo anti-tumor
activity. The author proposes the use of these physiological
LVs (similar to the one already approved by FDA) to translate
TCR-like CAR-T cells into clinic. Another important aspect to
improve the potency and safety of CAR-T cells stands on the
design of new tools that allow the clinicians to be able to
externally control their activity. Dr. Martin presented their
latest development on their transactivator-independent
doxycycline-regulated LVs (Lent-On-Plus). They showed the
potency of this system to induce any transgene in T cells both
in vitro and in vivo with very low doses of doxycycline. As proof
of concept, he also presented the ability to generate inducible
CAR-T cells that selectively kill CD19+ cells only in the presence
of doxycycline. However, the author envision that this approach
will be more applicable for future development of inducible
TRUCKs (iTRCKs), expressing any desired cytokine (factor)
upon the addition of doxycycline.ALLOGENEIC/”OFF-THE-SHELF”
THERAPY WITH CAR-T CELLS
The generation of autologous CAR-T cells for therapeutic
treatment implies many challenges related to i. the isolation of
circulating lymphocytes from heavy pre-treated patients who
might have lymphopenia; ii. the manufacturing of the cells; iii.
the logistics of collection of the starting material, preparation and
delivery for infusion of the medicinal product into patients; iv the
inter-patient variability in the yield and quality of the cell
product. The major advantage of generating universal CAR-T
cells is their “off-the-shelf availability, without delay in the
treatment and suitability for multiple infusions of engineered T
cells. Moreover, the manufacturing of universal CAR-T cells
allows the implementation of the standardization of batches of
cells and to reduce the costs of production. The strategy to
generate anti-tumor CAR-T cells starting from peripheral blood
lymphocytes isolated from healthy donors, has also the potential
to overcome the impairment of effector functions of patient-
derived CAR-T cells.
Universal CD19-CAR-T cells (UCART19) represent the first
“off-the-shelf” CAR-T cell product targeting CD19 expressing
malignancies (Dr. Reuben Benjamin, King’s College Hospital,
UK). In this product, anti-CD19 scFv-41BB-CD3z CAR is
expressed in T cells, with KO of TRAC and CD52 genes to
prevent GvHD in HLA mismatched patients. The TRAC and
CD52 gene KO has been performed through the usage of TALEN
(41). In addition, RQR8 epitope, that is a mimotope of CD20 has
been introduced into engineered T cells as a safety switch (131).January 2021 | Volume 11 | Article 589381
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patients with diagnosis of ALL have been tested in the context of
the PALL/CALM study following lymphodepleting regimens and
to evaluate the maximum tolerated dose (MTD). The study
revealed that UCART19 has a safety profile, with no acute
GvHD and severe toxicities, leading to 67% of CR (40, 43, 132).
Different strategies of gene editing are in place for allogeneic
CAR-T cells for the knock-out of genes involved in either GvHD,
such as TCRab - TRAC, TCRBC1, TCRBC2, rejection molecules
(e.g., CD52, b2 microglobulin), or molecules associated with the
exhaustion of T cells (e.g., PD-1, CTLA-4) (42, 44). CAR-T cell
approaches in infant ALL patients have sometimes encountered
difficulties in generating autologous CAR-T cells and, moreover,
are associated with the risk of developing CD19-tumor cell
escape (Prof. Paul Veys, Great Ormond Street Hospital For
Children & UCL GOS Institute of Child Health, UK).
UCART19 represented a bridge between lymphodepletion/
CAR-T cell therapy and allogeneic HSCT. This strategy
allowed the eradication of CD19- malignant cells following
CAR-T cell therapy during the allogeneic HSCT, followed by
reconstitution of donor immune cells and elimination of residual
UCART cells. This procedure was followed by a 30-day transient
GCSF-dependent recovery of neutrophils and protracted
multilineage cytopenia until the second allo-SCT after 12
weeks. The TALEN trial achieved 60% clinical responses in
pediatric ALL patients. The effectiveness of TALEN versus
CRISPR/Cas9 was compared, indicating that the risk of GvHD
might be reduced with CRISPR/Cas9, as CAR insertion and
editing of TCR were coupled, leading to reduced potential
contamination of the final product with TCR positive cells.
The generation of CAR-T cells from umbilical cord blood
(UCB) coupled with gene editing has been explored in pre-
clinical models as alternative method to generate allogeneic
CAR-T cells with increased early differentiation features,
including increased proliferative capacity (133). The unmet
need is to define the optimal lymphodepletion regimen(s) and
whether allo-SCT is required post UCART infusion to extend the
clinical benefit of this cell-based therapy.
The usage of UCB as starting material to generate CAR-T
cells represented the object of one study ongoing at Sidra
Medicine (Dr. Cristina Maccalli, Sidra Medicine, Qatar). UCB
offers the unique capacity of broad HLA mismatch between
donor and host. The frequency of T lymphocytes in cord blood is
lower as compared to peripheral blood representing a limiting
factor for the generation of CAR-T cells. The CD19-CD28z
and CD19- 4-1BBz CAR-T cells have been isolated and
phenotypically characterized utilizing an in-house designed
multiparametric IF (including 28 markers) panels. The overall
phenotype at different time points (Day 0, + 7, +9, +14) of in
vitro culture of UCB vs. peripheral blood-CAR-T cells varied in
terms of the percentage of CD4+ and CD8+ stem/central memory
T cells. In addition, immunomodulating molecules such as PD-1,
TIM3, and LAG3 were differentially expressed in CAR-T cells
with different origins. The integration of different platforms,
such a flow cytometry, EliSpot, and FluoroSpot based cytokine
release and transcriptomic profiling (134) allowed theFrontiers in Immunology | www.frontiersin.org 10development of a proof of principle study aimed at identifying
the UCB-derived CAR-T cell population endowed with superior
anti-tumor activity. Further investigations are warranted to
validate these results (unpublished data).
CAR-NK cells represent a promising strategy for allogeneic
and universal cell-therapy (Dr. Tomas Bos, Glycostem
Therapeutics, The Netherlands). NK cells represent the 5%–
10% of circulating immune cells and are members of innate
immune control with low risk, due to their independence on the
recognition of MHC/peptide complexes, of allogeneic rejections
or GvHD upon their infusion in cancer patients. The generation
of clinical grade NK cells has been optimized in the presence of a
liquid cell culture containing differentiation factors and an
artificial niche composed of glycosaminoglycans. The NK cell
product, denominated oNKord®, showed strong cytotoxicity
against CRC, regardless of the mutational status of EGFR and
RAS (135), and leukemia both in vitro and in mouse models
(136). Interestingly, this type of treatment in a phase I clinical
trial for AML patients following conditioning with Flu/Cy,
showed safety, no toxicities or sign of GvHD and clinical
efficacy with improvement of survival (34 months) (137).
The repertoire of available gene editing tools for CAR-T cells
has been discussed by Dr. Karim Benabdellah (GENYO, Spain;
Oral Abstract Presentation), highlighting that the insertional
deficient LV episomes (IDLV) combined with CRISPR/CAS-9
can implement the effciency of CD19-CAR-T cells for the KO of
TCR to prevent in vivo allogeneic rejection and GvHD. These
CAR-T cells can maintain both in vitro and in vivo the reactivity
against tumor cells.THE USAGE OF maB N CANCER
THERAPY AS A COMPLEMENTARY OR
INTEGRATIVE APPROACH FOR
ENGINEERED IMMUNE CELLS
Several mAbs have been registered as standard of care for different
types of tumors. Some of them, through the binding to the Fcg
receptor (FcgR) on effector cells, such as NK and gd T cells, can
activate the antibody-dependent cell-mediated cytotoxicity
(ADCC) that can lead to the killing of malignant cells (Prof.
Hans van der Vliet, Amsterdam University Medical Center,
Cancer Center Amsterdam, The Netherlands). Bispecific Ab,
bearing two epitope binding regions, have been designed to bind
simultaneously to two target molecules and can be used to target
immune effector cells to tumor cells. Trifunctional hybrid
antibodies (Triomabs) are formed by combining two halves of
distinct mAbs, for example of rat and mouse mAb origin, which, as
a result of species preferential heavy-light chain pairing, reduces
random pairing of heavy and light chains simplifying
manufacturing. In addition, to facilitate the interaction of
immune cells with target cells, Triomabs (e.g., catumaxomab,
ertumaxomab) can also mediate ADCC through the FcgR (138–
141). Notably, other bispecific antibody formats utilize a linking of
single chain Fv (scFv) fragments with different antigen specificity,January 2021 | Volume 11 | Article 589381
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bispecific antibody in a tandem orientation (TaFv) is
blinatumomab, an anti-CD3 and anti-CD19 bispecific T cell
engager (BiTE) used for the treatment of, e.g., relapsed or
refractory B-ALL, that showed an improvement of complete
remission rate and of OS as compared with chemotherapy (53,
142). Multiple alternative bispecific antibody platforms (e.g.,
bispecific diabodies, Fc-containing bispecific antibodies,
immunocytokines, prodrug bispecifics, and MHC class I
targeting bispecifics) are under development in an effort to
further improve the clinical efficacy of such approaches and to
extend their application towards other disease indications (143–
145). The generation of novel antigen-specific scFv could also
complement the function of CARs, either by enhancing the binding
to target molecules or expanding the tools to redirect CAR-T cells
to tumor sites. In addition, the usage of mAbs, including the
bispecific, either in combination with CAR-T cells or encoded
simultaneously with CARs by LV vectors, can represent an
interesting approach to enhance the homing of CAR-T cells to
the tumor site, their penetration into the TME and the anti-tumor
activity (e.g., armored CAR-T cells discussed in paragraph 6).CONCLUSIONS
The development of engineered immune cells, T lymphocytes and
NK cells, represents a breakthrough of cancer immunotherapy
for both blood and solid tumors (see Tables 1 and 2). For the
first time, one of these innovative therapeutic strategies (CAR-T
cells) has been approved as standard of care for some
hematological malignancies. Nevertheless, the optimization
of these interventions, in terms of identification of novel TAs,
the improvement of the survival and the limitation of
differentiation, aging and exhaustion of T cells, as well as of
associated toxicities upon in vivo infusion and their capacity
to penetrate TME are under investigation. Several platforms
and approaches have been developed to mitigate the
aforementioned limitations of anti-tumor cell-based therapies,
contributing to the rapid evolution of the field. Furthermore,
novel Ab-based tools designed on tumor cell phenotype and
cancer immune setpoints are warranted to design more
effective personalized Ab-based weapons for cancer therapy.
The development of these approaches has required long path
for R&D, however, the gained expertise could facilitate the
implementation of the molecular and genomic tools to generate
anti-tumor cell therapy with superior clinical efficacy.
Nevertheless, the discussion occurring in the context of the
conference highlighted the need of specialized manufacturing
facilities and clinical centers, including multidisciplinary
personnel, for the production, delivery and infusion into
patients, as well as their clinical monitoring and follow-up.
The development of inter- and intra-regional networks is of
high relevance to facilitate the establishment of these cell-
therapy centers and to expand the accessibilities to these
therapeutic interventions to a broad number of cancer
patients. The costs associated with the development of thisFrontiers in Immunology | www.frontiersin.org 11type of centers and with the clinical grade manufacturing of
these cellular medicinal products should also be taken into
account. The access of patients to these therapies and their
attractiveness for clinical application might increase whether a
point-of-care manufacturing model would be designed and
established. The role of pharma and biotech has been shown
to be critical and to facilitate the clinical grade development of
these approaches. The interaction and cooperation between
academia and industry were emphasized during the sessions’
discussions as in need of being potentiated and initiated even at
early phase of R&D. Further investigations are also required to
simplify the manufacturing of engineered immune cells and
potentiate the development and safety of allogeneic products.
The exploration of the combination therapies (such as with
immunomodulating agents and/or standard therapies) could
represent a strategy to overcome the development of resistance
to cell-based therapies and to target a broad variety of tumors.
A consensus regarding the need of continuous exchange of
information among investigators and clinicians and of the
development of international networks and collaborations
resulted from the participants to the workshop.THE EICCI FACULTY GROUP
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